CAR-T therapies are of intense interest at the moment, but the total cost of a regimen is estimated by the Wall Street Journal between $463 and $968 thousand. If the patient has an adverse reaction, like a cytokine storm, the price will necessarily go higher and CAR-T will rarely be the first therapy tried. No doubt CAR-T has its charms, but it is yet another therapy with such a breath-taking price tag that cost will be a barrier to general adoption. Like the numerous $1 million plus gene therapies, there will be young patients for whom such an expenditure can be justified, but GBM tends to strike an older population where cost will be more of an issue.
What works in the laboratory isn't necessarily going to be an economically sustainable therapy for the general population. I wish that wasn't the case, but the reality is that cost increasingly matters.